Immunohistochemistry Core Laboratory

免疫组化核心实验室

• 批准号: 7733482
• 负责人: Mark Raffeld
• 金额: $ 40.65万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7733482
• 关键词: Alveolar Soft Part Sarcoma; Antibodies; B-Lymphocytes; Biological Markers; C-KIT Gene; CCAAT-enhancer-binding protein-delta; CCR; CD19 gene; CD8B1 gene; CDW52 gene; CTAG1 gene; CXCL13 gene; Cell Cycle; Cell Therapy; Cells; Chemotherapy-Oncologic Procedure; Chimeric Proteins; Clinical; Clinical Services; Collaborations; Communities; Cyclin D1; Development; Diagnostic; Diagnostic Services; Discrimination; Disease; Enrollment; Epidermal Growth Factor Receptor; Frozen Sections; Genes; Growth Factor Receptors; IFN consensus sequence binding protein; IL2RA gene; Immune; Immunohistochemistry; Keratin; Laboratories; Lymphoma; MART-1 Tumor Antigen; MS4A1 gene; Malignant Neoplasms; Molecular Target; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; Operative Surgical Procedures; Ovarian; PTEN gene; Paraffin; Phase; Play; Process; Prognostic Marker; Proliferation Marker; Publications; Receptor Protein-Tyrosine Kinases; Research; Research Personnel; Research Project Grants; Research Support; Resources; Role; Services; Signal Pathway; Signal Transduction; Slide; Surgical Pathology; TFE3 gene; TP53 gene; Testing; Time; Tissues; Topoisomerase Inhibitors; Topotecan; Translational Research; United States National Institutes of Health; base; gp100 Antigen; macrophage; novel; p27 Cell Cycle Protein; p27 Enzyme Inhibitor; response; transcription factor; transdifferentiation

The immunohistochemistry core laboratory processed over 4150 cases in 2007, producing about 32,500 immunostained slides for clinical service. The laboratory produces an additional 3000 slides in support of a variety of research projects, requested by both LP clinical researchers and NCI/NIH researchers from outside of LP. The laboratory tests include a panel of over 170+ paraffin reactive antibodies, and 40 additional antibodies for frozen section studies. These include cell of origin diagnostic markers, cell signaling pathway activation markers, proliferation-related markers, and other prognostic markers. At any given time, the laboratory is developing or testing 5 or more novel antibodies for potential clinical or research use. Examples of new antibody tests developed by the service include type specific keratin antibodies, newly developed paraffin reactive CD markers including CD4, CD5, CD8, CD25, CD38, CD138, CD163, CXCL13, tissue specific transcription factors and cell cycle regulators. Examples of the latter include MYF-4, CYCLIN D1, p27, HIF-1a, MITF, TFE3, FOXP3, OCT-2, BOB-1, PU-1, PTEN, p-AKT, p-S6K, p-MTOR and several growth factor receptors such as c-KIT, EGRF, and ERB-2. The immunohistochemistry core laboratory supports translational research of both NCI and NIH researchers, and in 2007/8 provided research support to over 20 different NCI and NIH laboratories. Collaborations resulting in publications in 2008 are attached, and include studies with: Dr. Esta Sterneck -- Role of C/EBP delta gene in ovarian function Dr. Elaine Jaffe -- Transdifferentiation studies in lymphomas Dr. David Vistica -- Immunohistochemical discrimination of ASPL-TFE3 fusion proteins in Alveolar Soft Part Sarcoma Dr. Alex Vortmeyer -- Cancer development in VHL Diseases Dr. Herbert Morse -- Role of IRF-8 in macrophages and B-cells Dr. Wyndham Wilson -- Role of biomarkers in response to novel chemotherapy regimens in lymphomas Among the many other NCI and NIH tenured investigators and clinicians that have utilized the laboratory's resources in the past year are: Dr. Mark Hallett (NINDS) Dr. Theo Heller (NIDDK) Dr. Steven Holland (NIAID) Dr. Steven Jacobson (NINDS) Dr. John Janik (NCI) Dr. David Kleiner (NCI) Dr. Kenneth Kraemer (NCI) Dr. Giovanni Melillo (NCI-Frederick) Dr, Stefania Pittaluga (LP-NCI) Dr. Robert Purcell (NIAID) Dr. Steven Rosenberg (CCR-NCI) Dr. Martha Quezado (NCI) Dr. Maria Tsokos (LP-NCI) Dr. Alan Wayne (CCR-NCI) Dr. Adrian Weistner (NHLBI)

2007年，免疫组织化学核心实验室在4150例病例中处理了4150例，可为临床服务产生32,500张免疫染色幻灯片。 LP临床研究人员和LP以外的NCI/NIH研究人员都要求提供另外3000个幻灯片，以支持各种研究项目。实验室测试包括一组超过170多种石蜡反应性抗体，以及40种用于冷冻切片研究的其他抗体。其中包括原点诊断标记，细胞信号通路激活标记，与增殖相关的标记和其他预后标记。在任何给定时间，实验室正在开发或测试5种或更多新型抗体，用于潜在的临床或研究用途。该服务开发的新抗体测试的实例包括类型特定角蛋白抗体，新开发的石蜡反应性CD标记，包括CD4，CD5，CD8，CD8，CD25，CD38，CD38，CD138，CD163，CXCL13，CXCL13，组织特异性转录因子和细胞周期调节剂。后者的示例包括MyF-4，Cyclin D1，P27，HIF-1A，MITF，TFE3，FOXP3，OCT-2，BOB-1，PU-1，PTEN，PTEN，P-S6K，P-S6K，P-S6K，P-MTOR和几种生长因子受体，例如C-KKIT，EGRF，EGRF和ERB-2。免疫组织化学核心实验室支持NCI和NIH研究人员的转化研究，并在2007/8年为20多种不同的NCI和NIH实验室提供了研究支持。 Collaborations resulting in publications in 2008 are attached, and include studies with: Dr. Esta Sterneck -- Role of C/EBP delta gene in ovarian function Dr. Elaine Jaffe -- Transdifferentiation studies in lymphomas Dr. David Vistica -- Immunohistochemical discrimination of ASPL-TFE3 fusion proteins in Alveolar Soft Part Sarcoma Dr. Alex Vortmeyer -- Cancer development in VHL Diseases Dr. Herbert Morse -- Role of IRF-8 in macrophages and B-cells Dr. Wyndham Wilson -- Role of biomarkers in response to novel chemotherapy regimens in lymphomas Among the many other NCI and NIH tenured investigators and clinicians that have utilized the laboratory's resources in the past year are: Dr. Mark Hallett (NINDS) Dr. Theo Heller (NIDDK) Dr. Steven Holland (NIAID) Steven Jacobson博士（Ninds）博士John John John Kleiner博士（NCI）博士Kenneth Kraemer博士（NCI）Giovanni Melillo博士（NCI-FREDERICK），Stefania Pittaluga博士（NCI）Maria Tsokos博士（LP-NCI）Alan Wayne博士（CCR-NCI）Adrian Weistner博士（NHLBI）